Carola Wagner
3 IP cases indexed. Covers patent matters.
Cases Presided Over
3 cases indexed | Page 1 of 1
Sanofi SA as successor of Sanofi Mature IP a.o. v.Reddy Pharma SAS a.o.
This case concerned European Patent 2,493,466, held by Sanofi SA, relating to a novel anti-tumoral use of cabazitaxel for treating prostate cancer. Sanofi filed infringement actions against STADA, Dr. Reddy, and Zentiva entities for marketing generic versions of its JEVTANA product, while the defendants filed counterclaims for revocation. The Local Division Munich revoked the patent in its entirety for lack of inventive step, dismissed the infringement actions, and ordered Sanofi to bear the costs.
BOEHRINGER INGELHEIM INTERNATIONAL GMBH v.ZENTIVA PORTUGAL, LDA
Boehringer Ingelheim, proprietor of European patent EP 1 830 843 covering nintedanib for treating fibrotic diseases including idiopathic pulmonary fibrosis (IPF), sought provisional measures against Zentiva, which held Portuguese marketing authorisations for generic nintedanib products and had completed national pricing and reimbursement procedures. The Lisbon Local Division denied the application, finding no imminent infringement, but the Court of Appeal reversed, holding that completion of national health technology assessment, pricing and reimbursement procedures can constitute imminent infringement. The Court of Appeal granted a provisional injunction against Zentiva across all UPC territories where the patent is in force, coupled with recurring penalty payments, and ordered Zentiva to pay €199,000 in interim costs.
Medac Gesellschaft für klinische Spezialpräparate m.b.H. v.Respondent
This procedural order concerns an application by Medac Gesellschaft für klinische Spezialpräparate m.b.H. under Rule 262.1(b) RoP in infringement proceedings (UPC_CFI_146/2024) involving Sanofi entities as claimants and STADA entities as defendants regarding European patent EP 2 493 466. Medac had uploaded a privileged and confidential letter from Sanofi as 'Exhibit 2' in unredacted form, prompting objections from Sanofi. The court permitted the withdrawal of the application and the exhibit, ordered Medac to bear the costs of removing the exhibit from the CMS, imposed a recurring penalty for any future use of the document, and issued a warning to Medac's representative for negligent breach of the Code of Conduct.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.